Does Adding Zevalin® to Reduced Intensity Regimen (RIC) of Fludarabine and Melphalan Improve Outcome of Patients with Relapsed/Refractory B-Cell Lymphoma Who Were Chemoresistant and FDG PET Positive at the Time of Allo-HCT?
Year: 2016
Type: article
Abstract: Relapse remains a major cause of treatment failure in patients with relapsed/refractory B-NHL undergoing RIC allo-HCT, especially in chemoresistant or PET positive disease. Zevalin® offers the advantage of targeted radiation delivery to disease sites and is an effective therapy for B-cell NHL. We hypothesized that adding Zevalin® to Fludarabine and melphalan (Flu/Mel) may improve disease control in PET positive and chemoresistant disease thus reducing the risk of relapse post allo-HCT.
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2433839883